Gastrointestinal Biomarkers

20% 20% 20% 20% 20% Biomarker Assay Purpose Drug(s) Diagnostic Test Test ID PD-L1 Gastric, GEJ, esophageal adenocarcinoma; ESCC Pembrolizumab, Nivolumab PDL1 Dako 22C3 PharmDX PDL1UPPERGIMARCH2026 Claudin 18.2 Gastric or GEJ adenocarcinoma Zolbetuximab VENTANA CLDN18 (43-14A) RxDx BMCLAUDIN18

Head & Neck Biomarkers

20% 20% 20% 20% 20% Biomarker Assay Purpose Drug(s) Diagnostic Test Test ID PD-L1 Head and neck squamous cell carcinoma (HNSCC) Pembrolizumab PDL1 Dako 22C3 PharmDX PDL1HNSCC22C3PEMBRO

Gyne Biomarkers

20% 20% 20% 20% 20% Biomarker Assay Purpose Drug(s) Diagnostic Test Test ID PD-L1 Cervical cancer (SCC and Adenocarcinoma) Pembrolizumab PDL1 Dako 22C3 PharmDX PDL1CERVIX CEP17 SISH Ploidy Analysis N/A VENTANA Inform Chromosome 17 probe MOLARCEP17

Lung Biomarkers

20% 20% 20% 20% 20% Biomarker Assay Purpose Drug(s) Diagnostic Test Test ID PD-L1 NSCLC stage II to IIIA Atezolizumab PDL1 SP263 PDL1NSCLCATEZOSP263

Breast Biomarkers

20% 20% 20% 20% 20% Biomarker Assay Purpose Drug(s) Diagnostic Test Test ID PD-L1 Triple Negative Breast Cancer (TNBC) Pembrolizumab PDL1 Dako 22C3 PharmDX PDL1TNBC22C3PEMBRO